

**Title:** Association between rRT-PCR test results upon admission and outcome in hospitalized chest CT-Positive COVID-19 patients; a provincial retrospective cohort with active follow-up

**Abbreviated Title:** Association between COVID-19 rRT-PCR test results and outcome

**Authors and Affiliations:** Saeed Nemati<sup>1</sup>, Hamid Reza Najari<sup>2&3</sup>, Anita Eftekharzadeh<sup>4</sup>, Amir Mohammad Kazemifar<sup>2</sup>, Ali Qandian<sup>5</sup>, Pedram Fattahi<sup>1</sup>, Maedeh Zokaei Nikoo<sup>6</sup>, Shiva Leghaei<sup>5</sup>, and Mohammad Reza Rouhollahi<sup>1&7</sup>

<sup>1</sup> Cancer Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran

<sup>2</sup> Department of Internal Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

<sup>3</sup> Deputy of health, Qazvin University of Medical Sciences, Qazvin, Iran

<sup>4</sup> Obesity Research Center, Research Institute for Endocrine Centers, Shahid Beheshti University School of Medicine, Tehran, Iran

<sup>5</sup> Office of Communicable Disease, Deputy of health, Qazvin University of Medical Sciences, Qazvin, Iran

<sup>6</sup> Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran

<sup>7</sup> Clinical Cancer Research Center (CCRC), Milad Hospital, Tehran, Iran

The study was performed at Qazvin University of Medical Sciences, Qazvin, Iran

**Corresponding Author:**

Mohammad Reza Rouhollahi, MD

Cancer Research Center, Cancer Research Institute

Tehran University of Medical Sciences

Keshavarz Blvd, Tehran, Iran

Phone: +98-21-66581638

Cell: +98-912-3799228

Fax: +98-21-66581542

Email: [mr-rouhollahi@razi.tums.ac.ir](mailto:mr-rouhollahi@razi.tums.ac.ir)

# Association between rRT-PCR test results upon admission and outcome in hospitalized chest CT-positive COVID-19 patients; a provincial retrospective cohort with active follow-up

## Abstract

**Background** –The Covid-19 pandemic imposed the most devastating challenge on healthcare systems worldwide. Iran was among the first countries that had to confront serious shortages in RT-PCR testing for SARS-CoV-2 and ventilators availabilities throughout the COVID-19 outbreak. This study aimed to investigate the clinical course of hospitalized COVID-19 patients with different rRT-PCR test results during the first 3 weeks of the outbreak in Qazvin province, Iran.

**Methods** – For this retrospective cohort study, data of hospitalized patients primarily diagnosed as having COVID-19 in all 12 centers across the whole Qazvin province during Feb 20-Mar 11, 2020 was analyzed. A multivariate logistic regression model was applied to assess the independent associates of death among COVID-19 patients.

**Results** – 998 patients (57% male, median age 54 years) with positive chest CT-scan changes were included in this study. Among them, 558 patients were examined with rRT-PCR test and 73·8% tested positive. Case fatality rate was 20·68% and 7·53% among test-positive and test negative hospitalized patients, respectively. While only 5·2% of patients were ICU admitted, case fatality rates outside ICU were 17·70% and 4·65% in test-positive and test-negative non-ICU admitted patients, correspondingly. The independent associates of death were age  $\geq$  70 years, testing positive with rRT-PCR test, having immunodeficiency disorders and ICU admission.

**Conclusions** – Hospitalized COVID-19 patients with mild symptoms despite positive chest CT changes and major comorbidities were more probable to have negative rRT-PCR test result, hence lower case fatality rate and a more favorable outcome.

**Keywords:** COVID-19 – Iran – Chest CT-scan – rRT-PCR

## Introduction

The first report of COVID-19 in Iran was officially announced on February 19, 2020, from the city of Qom in central Iran.<sup>(1)</sup> Shortly thereafter, cases of infection with the novel coronavirus were reported from all over the country. The province of Qazvin, including its capital - city of Qazvin which is located 200 km away from Qom, the coronavirus epicenter - was affected almost early during the COVID-19 epidemic in Iran. The province had a population of 1,300,000 people and accounted for 8% of the country's economy.<sup>(2)</sup> The first patient with a proven COVID-19 diagnosis in the province – a man in his mid-80s - was announced dead on March 1. This was also the first related death that was reported in Qazvin province.

To address the encountered challenges, the first edition of Iran National Interim Guidance on COVID-19 Diagnosis and Treatment (INIGCDT), which was published on February 24, limited the indications for rRT-PCR testing to detect SARS-CoV-2 to those admitted with severe respiratory signs and symptoms or admitted patients with fever whose chest imaging revealed pulmonary infiltration.<sup>(3)</sup>

During the less known COVID-19 outbreak in Iran, it was presumed that the rapid progression of infected and thus hospital admitted patients would soon overload the medical system. The problem would be even more prominent at the provincial level. In the “pre-overload” phase of the novel coronavirus epidemic in Qazvin - just before the rapid hospitalization rate across the province reached its peak capacity - a unique opportunity was provided to assess not only the clinical pattern and outcome of the disease, but also to evaluate the performance of care centers throughout the province. The results of such an assessment can further be employed as a basis for more precise admission criteria aimed at saving more lives in the subsequent critical phases of the epidemic.

In light of the above issues and considering that since the emergence of the novel coronavirus epidemic in Iran, little has been documented about the course and outcome of the affected patients in the country, this retrospective cohort study aimed to investigate the clinical pattern and outcome of patients admitted to the hospitals and intensive care facilities of Qazvin province, Iran in a critical 3-weeks period - from February 20 to March 11, 2020 - with a primary diagnosis of COVID-19 but different rRT-PCR test results.

## Methods

In this retrospective cohort study, patients who were admitted to all 12 hospitals across Qazvin province, Iran, during February 20 - March 11 with a primary diagnosis of COVID-19 (see definition) were included and followed-up until March 27, 2020.

Upon the outbreak, the Qazvin University School of Medicine – as the provincial health governor - provided an electronic data entry platform to collect epidemiologic and clinical data related to patients with COVID-19 and mandated all the involved hospitals within the province to employ the database. Data was collected from patients' medical records and entered into the electronic database during the patients' admission period. This included epidemiologic and clinical data, and patients' exposure history as well as their results of COVID-19 rRT-PCR test and the clinical outcome (discharge, death). The patients who were admitted to hospital during March 5 - March 11, 2020 (the last week of this study) were later followed-up by phone to confirm their outcome.

This study was approved by the Research Ethic Committee of Qazvin University of Medical Sciences (QUMS-EC).

## Criteria and definitions

Patients were admitted with a primary diagnosis of COVID-19 based on INIGCDT.<sup>(3)</sup> According to the guidance, patients were admitted with a primary diagnosis of COVID-19 if they had symptoms of fever, cough or myalgia (referred here as minor clinical criteria) and A) presented with either respiratory distress, low pulse oximetry reading ( $SpO_2 < 93\%$ ), respiratory rate (RR)  $> 30$  (addressed here as major clinical criteria) or had decreased level of consciousness or B) they were among the high risk groups who had an underlying medical condition along with suggestive chest X-ray or CT scan changes for COVID-19 (see below). Further laboratory and chest imaging studies were made during the patients' admission course.

A definitive diagnosis of COVID-19 was made by rRT-PCR test to detect SARS-CoV-2 in patients' respiratory secretions. The test became available through Iran Pasteur Institute in early February, 2020. Throat-swab and lower respiratory secretion (in intubated patients) specimens were obtained from patients and sent for SARS-CoV-2 PCR test during their admission course. However, due to a serious shortage in the test availability in Iran at that time, no re-examination was made for the patients.

Fever was defined as oral temperature  $> 37.8^\circ\text{C}$ . Shortness of breath and decreased level of consciousness were defined upon triage physicians' clinical judgement. Underlying medical conditions that justified patients' admission as proposed by INIGCDT included a history of cardiovascular diseases, pulmonary diseases, diabetes, hypertension, cancer, HIV infection, organ transplantation, Chest X-ray or CT scan changes suggestive for COVID-19 consisted of bilateral patchy infiltration with rapid progression toward ground glass opacity (GGO).<sup>(3)</sup>

Patients were admitted to intensive care units if they had persistent hypoxemia, decreased level of consciousness, hemodynamic instability, or hypercapnia.

People were discharged from the hospital if they had no fever for more than 48-72 hours, had SpO<sub>2</sub> > 93% while breathing room air, their respiratory and clinical symptoms and signs improved, and their serial chest imaging showed remarkable improvement.

### Patients follow-up

The patients who were admitted during the third week of this study period (March 5 - March 11, 2020) were actively followed-up using phone interviews on March 27. Among them, 436 patients (response rate=76.7%) were reached.

### Statistical analysis

Descriptive analysis was run using median (IQR). Patients were categorized based on weeks of admission, patients' outcome inside and outside the ICU and their rRT-PCR testing status. Case fatality rate (CFR) were assessed in each group. The Chi-Square test was employed to assess differences in study variables among the above categories of patients.

A multiple logistic regression model was applied to identify associated factors of death in COVID-19 infected patients. Odds Ratio (OR) and 95% CI for each contributing factor. Statistical analysis was performed using the Stata statistical software package (StataCorp. 2014. Stata Statistical Software: Release 14.1, College Station, TX: StataCorp LP) and a P value less than 0.05 was considered as significant.

## Results

Data of 1197 patients who were admitted to Qazvin province hospitals was entered into the Qazvin province COVID-19 electronic database during Feb 20-March 11, 2020. Among them, a group of 191 PCR-negative patients who were admitted to non-COVID-19 wards was left out from analysis, however, their clinical course was followed up as well. The case fatality rate (CRF) among these patients was 3.1% and none of them were admitted to intensive care units. Furthermore, 8 patients whose death occurred within the first 24 hours of their admission were excluded from the study (Fig 1).

A total of 998 patients (57% male) with a median (IQR 25-75) age of 54(25) years were analyzed. From among them, 558 of the patients were tested for COVID-19 and 412 patients had positive results, while rRT-PCR test was negative in 146 cases. ICU care was provided for 5.2% patients, while others patients were isolated in the designated wards receiving low-flow oxygen and medical therapy. (Table 1)

Comparing the study participants' characteristics between the four groups of survivors and non-survivors outside and inside the ICU, no sex difference in CFR was found ( $p=0.674$ ). Among non-survivors, except for the age group  $< 50$  years, death rates were higher outside the ICU than inside intensive care units. Also, the difference was more prominent among patients aged  $>70$  (23.04% vs 4.15%). Notably, in the rRT-PCR test-positive group, a 20.68% CFR was observed (Table 2).

When comparing the study participants based on their PCR test results, it was found that while individuals aged  $> 70$  years were more tested than the younger age groups, there was no statistically significant age difference between positive and negative rRT-PCR patients. Moreover,

patients receiving ICU care were more tested, while in non-ICU admitted patients, positive results were more prevalent. (Table 3).

The case fatality rate among admitted patients in Qazvin province was 11.7% (Table 1). However, the number differed between various groups (Table 4). Employing a multiple logistic regression model including age group, sex, type of hospital (teaching, non-teaching (high volume and low volume), week of admission, ICU admission, co-existing disorders and rRT-PCR test results to determine the associated factors of death in the patients showed that age>70 years (OR=5.2 95% CI 2.9-9.1,  $p<0.001$ ), ICU admission (OR=11.5, 95% CI 5.5-23.9,  $p<0.001$ ) and having positive rRT-PCR test results (OR=5.8, 95%CI 2.7-12.5,  $p<0.001$ ) were the main determinants of death in the patients. After adjustment for all confounding factors including sex, age, ICU admission, co-existing disorders, and weeks of admission, higher odds of death was observed in rRT-PCR positive cases compared to test-negative patients (OR=5.7, 95% CI 2.6-12.4,  $p<0.001$ ) (Table 4).

## Discussion

The present study which was conducted in the critical first 3 weeks of the novel coronavirus outbreak in Qazvin province, Iran, found that while CT-diagnosed COVID-19 patients with typical respiratory symptoms but negative rRT-PCR results had a 7.5% case fatality rate, the number was as high as 20.7% in the test-positive patients.

This study showed a similar case fatality rate between men and women (12.13% vs 11.19%,  $p=0.511$ ). This is in line with what has been previously reported from Wuhan, China.<sup>(4)</sup> On the other hand, as was previously presumed, the case fatality rate in patients aged > 70 years (OR=5.2, 95%CI 2.9-9.1) and in those who were ICU-admitted (OR=11.5, 95%CI 5.5-23.9)



were higher when compared to the reference group. Nevertheless, we did not find any statistically significant increased death rate among COVID-19 patients with co-existing diseases. The exception, however, was those with immunodeficiency disorders whose case fatality rate was about 4 times the reference group. (Table 3) In fact, in the regression model, age affected death both independently and through the “corridor” of comorbidities. On the other hand, the adverse effect of major comorbidities was apparently observed only in association with age, i.e., they had no independent role in the case fatality rate in this cohort of patients. On the contrary, Guan et al previously reported that among PCR-test-confirmed hospitalized patients, the composite endpoint including admission to ICU, invasive ventilation, and death was higher in those who had known comorbidities.<sup>(5)</sup> Also, one meta-analysis previously reported that certain comorbidities were more prevalent in severe COVID-19 patients.<sup>(6)</sup>

This study is among the first investigations that aimed to frame the current picture of the battle with the COVID-19 outbreak in one of Iran’s provinces in the first 3 weeks of the epidemic emergence. We consider the timing of this study - reporting the clinical pattern of hospitalized patients in an early period when the medical system is assumed not to have become overloaded yet - to be among the strengths of this study. Additionally, acquiring data from the electronic data entry platform, which was designated exclusively to collect the data of the COVID-19 patients during their course of admission, along with the sizable number of the patients, add to the robustness of this study results. However, the findings on the clinical pattern and outcome of the patients need to be interpreted in the context of our limitations. Among them, we need to emphasize on the low availability of PCR testing in Iran. Also we did not have access to data on the patients’ laboratory results, their smoking status, or the medications they received.

The applied diagnosis and treatment flowchart as was first proposed by the INIGCDT<sup>(3)</sup> merits further explanation. The guidance which had originally adapted the related World Health Organization (WHO) guidance,<sup>(7, 8)</sup> proposed chest imaging as the first diagnostic step to screen patients who require prompt hospitalization amid shortages in RT-PCR test kits in Iran. As a result, all hospital-admitted patients with suggestive SARS-CoV-2 symptoms - with or without comorbidities - underwent chest imaging (specifically chest CT-scan) in the province of Qazvin hospitals. From among them, 59.3% were tested with RT-PCR and 24.9% had negative results. The proportion of the negative test results is in line with previous findings. While there has been a significant correlation between throat swab and sputum sample viral loads,<sup>(9)</sup> one study examining the bio-distribution of SARS-CoV-2 in different body tissues, reported positive RT-PCR rates only in 72% of sputum specimens.<sup>(10)</sup>

Examining the concordance between chest CT-scan and PCR test results, a previous study from Wuhan, China, reported that chest CT sensitivity was 97% in RT-PCR-positive patients. On the other hand, in the PCR-negative patients, 75% had positive CT scan findings, 81% of whom were later considered as highly likely or probable cases in their study.<sup>(11)</sup> Another study also showed that the sensitivity of chest CT was significantly higher than RT-PCR in their patients (98% vs 71%).<sup>(12)</sup>

When categorizing the CT-diagnosed COVID-19 patients based on their RT-PCR test results, as expected, the worst scenario was reported in the group of patients with suggestive respiratory symptoms or underlying diseases who had positive PCR test results. They accounted for 41% of ICU admissions throughout the province with a 77% case fatality rate even after receiving ICU care. On the other hand, the group with negative PCR test results who had presented with suggestive clinical symptoms or had had underlying diseases accounted for 32% of ICU

admissions due to COVID-19 in the province, among them 71% recovered. It has been previously reported that negative PCR results might be due to lower viral load in patients' specimens.<sup>(13, 14)</sup> This might provide a possible explanation for the lower case fatality rate among the test-negative group.

In the “no-test” group, which comprised CT-positive patients who were not tested for RT-PCR despite having suggestive clinical symptoms or co-existent diseases, 3·6% were admitted to intensive care units, among which 66·7% recovered eventually. On the other hand, the overall case fatality rate between this no-test group and those with negative PCR results did not differ significantly (4·1% vs 7·5%). Considering that in the first weeks of the epidemic, PCR testing was reserved for patients in critical condition, one might presume that a rather preemptive transfer of patients to the ICU and providing them with early intensive care would partially explain the lower case fatality rate in this group.

Additionally, there was a group of study patients with negative PCR results who also lacked major clinical symptoms or significant comorbidities. These patients had the lowest case fatality rate (3·1%) and none of them were ICU-admitted. These non-COVID-19 hospitalized patients who were not included in the analysis may serve as a basis for comparing the admission course and outcomes of the study patients.

The importance of intensive care facilities availability in such an epidemic cannot be emphasized more. As officially announced by the Iran Ministry of Health, in 2018, there were a total of 8264 ICU beds nationwide, which were occupied by 453891 patients during the year-ending 2018 (occupancy rate 55 patients/bed/year). In Qazvin province, which includes 1·6% of Iran's population, there are 96 ICU beds available (7·7 beds/100,000 of the population), comprising 1·1% of the total ICU beds in Iran. In this study, among the 92 non-survivor individuals that

were treated outside intensive care units, 63% presented with shortness of breath and 66% had low pulse oximetry readings. On the other hand, among the 612 patients who presented with  $SpO_2 < 93\%$ , only 6.2% were admitted to intensive care units. Considering that the ICU admission rate in this study was 5.2% - i.e., 52 ICU beds out of the Qazvin province total ICU beds, it could be concluded that there has been a possible need for at least 90 additional ICU beds throughout the province, that if had been provided, more lives would be saved.

Interestingly, other studies have previously reported that while most people affected by COVID-19 present with a mild illness, about 14% progress to more severe forms of the disease that require hospitalization, and 5% need ICU care.<sup>(15-17)</sup>

We also need to briefly mention the process of RT-PCR testing in the study patients. Due to the considerable shortage in PCR test kits in Iran and according to the INIGCDT, physicians were encouraged to perform the test only in patients with critical conditions. Moreover, no re-testing was provided for patients with negative tests. While it has been reported that COVID-19 patients with more severe forms of the disease have higher viral loads and longer periods of viral-shedding,<sup>(7)</sup> testing protocol mentioned above might have affected the results on the association between positive PCR test results and case fatality rate as well.

In conclusion, this study observed that COVID-19 hospitalized patients with mild symptoms despite positive chest CT changes and major comorbidities were more probable to have negative rRT-PCR test results, hence a lower case fatality rate and a more favorable outcome. Conversely, positive rRT-PCR test results were more prevalent in patients presenting with low  $SpO_2$  or unconsciousness and was strongly associated with increased odds of death among chest CT-positive patients. Considering the serious shortage in ICU capacity, preemptive transfer of more vulnerable rRT-test-positive patients to the ICU might save their lives.

## Acknowledgements

*Financial Support.* None reported.

*Conflict of Interest.* All authors report no conflicts of interest relevant to this article.

*Manuscript preparation.* WE4H writing and editing services, Vancouver, Canada, provided medical writing and editing support in preparing this manuscript.

## References

- .1 Takian A, Raoofi A, Kazempour-Ardebili S. COVID-19 battle during the toughest sanctions against Iran. *The Lancet*. 2020;395(10229):1035-6.
- .2 Iran National census 2016. Statistical center of Iran website. <https://www.amar.org.ir/english/Population-and-Housing-Censuses>. Published. Accessed April 3, 2020.
- .3 Iran National Interim Guidance on COVID-19 Diagnosis and Treatment 2020. Iran Ministry of Health, Deputy of Health. Available from: [http://dme.behdasht.gov.ir/uploads/Felo\\_Tashkish.pdf](http://dme.behdasht.gov.ir/uploads/Felo_Tashkish.pdf). Accessed April 3, 2020 [Persian]
- .4 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395(10229):1054-62.
- .5 Guan W-j, Liang W-h, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *European Respiratory Journal*. 2020:2000547.
- .6 Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020. Epub 2020/03/17.
- .7 Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. *The Lancet Infectious diseases*. 2020. Epub 2020/03/23.
- .8 World Health Organisation. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. Geneva: World Health Organization, 2020. Report No.: Contract No.: WHO/COVID-19/laboratory.2020.4/
- .9 Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. *The Lancet Infectious diseases*. 2020;20(4):411-2. Epub 2020/02/28.
- .10 Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *Jama*. 2020.

- .11 Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology*. 2020:200642. Epub 2020/02/27.
- .12 Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. *Radiology*.0(0):200432.
- .13 Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. *Radiology*.0(0):200343.
- .14 Liu J, Yu H, Zhang S. The indispensable role of chest CT in the detection of coronavirus disease 2019 (COVID-19). *European journal of nuclear medicine and molecular imaging*. 2020. Epub 2020/04/05.
- .15 World Health Organisation. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020. Geneva: World Health Organization, 2020 2020. Report No.: Contract No.: WHO/nCoV/Clinical/2020.3.
- .16 Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine*. 2020. Epub 2020/02/29.
- .17 Epidemiology NCPER. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. *Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi*. 2020;41(2):145.

Table 1: Basic characteristics of the study participants

<b>Variable</b>	<b>Week 1 N= 116</b>	<b>Week 2 N= 399</b>	<b>Week 3 N= 483</b>	<b>Total N= 998</b>
<b>Sex</b>				
Female	57 (49·14%)	168 (42·11%)	204 (42·24%)	429 (42·99%)
Male	59 (50·86%)	231 (57·89%)	279 (57·76%)	569 (57·01%)
<b>Age group</b>				
< 50 years	55 (47·41%)	167 (41·85%)	180 (37·27%)	420 (40·28%)
51-60 years	21 (18·10%)	86 (21·55%)	85 (17·60%)	192 (19·24%)
61-70 years	17 (14·66%)	74 (18·55%)	96 (19·88%)	187 (18·74%)
≥70 years	23 (19·83%)	72 (18·05%)	122 (25·26%)	217 (21·74%)
<b>Admission Criteria</b>				
Minor clinical criteria <sup>1</sup> plus at least 1 major criteria <sup>2</sup>	92 (79·31%)	317 (79·45%)	378 (78·26%)	787 (78·86%)
Co-existing disorders OR Immunodeficiency <sup>3</sup>	24 (20·69%)	82 (20·55%)	105 (21·74%)	211 (21·14%)
<b>rRT-PCR test status</b>				
Positive	33 (28·45%)	200 (50·13%)	207 (42·86%)	440 (44·09%)
Negative	20 (17·24%)	49 (12·28%)	77 (15·94%)	146 (14·63%)
Not tested	63 (54·31%)	150 (37·59%)	199 (41·20%)	412 (41·28%)
<b>ICU admission</b>				
No	108 (93·10%)	377 (94·49%)	461 (95·45%)	946 (94·70%)
Yes	8 (6·90%)	22 (5·51%)	22 (4·55%)	52 (5·21%)
<b>Co-existing Disorder</b>				
Two or more comorbidities	12 (12·12%)	32 (9·94%)	36 (9·00%)	80 (9·74%)
Cardiovascular Diseases	16 (13·79%)	41 (10·28%)	53 (10·97%)	110 (11·02%)
Diabetes	13 (11·21%)	43 (10·78%)	49 (10·14%)	105 (10·52%)



Hypertension	4 (3·45%)	30 (7·52%)	23 (4·76%)	57 (5·71%)
Chronic Pulmonary Diseases	4 (3·45%)	17 (4·26%)	9 (1·86%)	30 (3·01%)
Immunodeficiency <sup>3</sup>	1 (0·86%)	6 (1·50%)	9 (1·86%)	16 (1·60%)
Chronic Renal Diseases	1 (0·86%)	4 (1·00%)	5 (1·04%)	10 (1·00%)
Total	30 (25·86%)	111 (27·82%)	124 (25·67%)	265 (26·55%)

### Hospital type

Teaching	92 (79·31%)	317 (79·45%)	360 (74·53%)	769 (77·05%)
High volume non-teaching	17 (14·66%)	78 (19·55%)	117 (24·22%)	212 (21·24%)
Low volume <sup>4</sup> non-teaching	7 (6·03%)	4 (1·00%)	6 (1·24%)	17 (1·70%)

### Outcome

Recovery	104 (89·66%)	352 (88·22%)	425 (87·99%)	881 (88·28%)
Death	12 (10·34%)	47 (11·78%)	58 (12·01%)	117 (11·72%)

Variables are presented in numbers (%). Minor clinical criteria: Fever, cough, and myalgia; Major clinical criteria: Low SpO<sub>2</sub>, shortness of breath, unconsciousness; Immunodeficiency include HIV infection and AIDS, cancer, immunodeficiency disorders and receiving chemotherapy; Low volume hospitals indicate hospitals with less than 20 COVID-19 admitted patients.

Table 2: Comparing different prognostic factors between survivors and non-survivors in ICU admitted and non-ICU admitted patients

Variables	Non survivors N=117 (11.7%)			Survivor N=881 (88.3%)		P value
	Total N=998	Outside ICU N= 92	Inside ICU N= 25	Outside ICU N= 854	Inside ICU N= 27	
<b>Sex</b>						
Female	429 (42.99%)	40 (9.32%)	8 (1.87%)	368 (85.78%)	13 (3.03%)	
Male	569 (57.01%)	52 (9.14%)	17 (2.99%)	486 (85.41%)	14 (2.46%)	0.674
<b>Age group</b>						
<50 years	420 (40.28%)	17 (4.05%)	7 (6.67%)	372 (88.57%)	6 (1.43%)	
51-60 years	192 (19.24%)	9 (4.69%)	3 (1.56%)	174 (90.63%)	6 (3.13%)	
61-70 years	187 (18.74%)	16 (8.56%)	6 (3.21%)	160 (85.56%)	5 (2.67%)	
≥70 years	217 (21.74%)	50 (23.04%)	9 (4.15%)	148 (68.20%)	10 (4.61%)	<b>&lt;0.001</b>
<b>RT-PCR test status</b>						
Positive	440 (44.09%)	74 (16.82%)	17 (3.86%)	344 (78.18%)	5 (1.14%)	
Negative	146 (14.63%)	6 (4.11%)	5 (3.42%)	123 (84.25%)	12 (8.22%)	
Not tested	412 (41.28%)	12 (2.91%)	3 (0.73%)	387 (93.93%)	10 (2.43%)	<b>&lt;0.001</b>
<b>Symptoms</b>						
Fever	545 (54.61%)	50 (9.17%)	8 (1.47%)	476 (87.34%)	11 (2.02%)	0.053

Cough	666 (66.73%)	63 (9.46%)	15 (2.25%)	583 (87.54%)	8 (1.20%)	<b>&lt;0.001</b>
Myalgia	301 (30.16%)	22 (7.31%)	3 (1.00%)	271 (90.03%)	5 (1.66%)	<b>0.039</b>
Shortness of breath	573 (57.42%)	58 (10.12%)	21 (3.67%)	477 (83.25%)	17 (2.97%)	<b>0.022</b>
SpO <sub>2</sub> <93%	612 (61.32%)	61 (9.97%)	17 (2.78%)	513 (83.82%)	21 (3.43%)	0.166
Unconsciousness	31 (3.11%)	4 (12.90%)	7 (22.58%)	12 (38.71%)	9 (29.03%)	<b>&lt;0.001</b>
Minor Clinical Criteria	185 (18.54%)	13 (7.03%)	3 (1.62%)	166 (89.73%)	3 (1.62%)	0.343
Major Clinical Criteria	17 (1.70%)	3 (17.65%)	6 (35.29%)	3 (17.65%)	5 (29.41%)	<b>&lt;0.001</b>
<b>Co-existing disorders</b>						
Cardiovascular Disease	110 (11.02%)	20 (18.18%)	6 (5.46%)	81 (73.64%)	3 (2.73%)	<b>0.001</b>
Diabetes	105 (10.52%)	15 (14.29%)	4 (3.81%)	84 (80.00%)	2 (1.91%)	0.189
≥2 Co-morbidities	80 (9.74%)	15 (18.75%)	5 (6.25%)	55 (68.75%)	5 (6.25%)	<b>&lt;0.001</b>
Hypertension	57 (5.71%)	7 (12.28%)	5 (8.77%)	41 (71.93%)	4 (7.02%)	<b>0.001</b>
Chronic Pulmonary Disease	30 (3.01%)	4 (13.33%)	1 (3.33%)	23 (76.67%)	2 (6.67%)	0.435
Immunodeficiency	16 (1.60%)	2 (12.50%)	3 (18.75%)	10 (62.50%)	1 (6.25%)	<b>&lt;0.001</b>
Chronic Renal Disease	10 (1.00%)	2 (20.00%)	2 (20.00%)	6 (60.00%)	0 (0.00%)	<b>0.002</b>
<b>Weeks of Admission</b>						
1st week	116	8 (6.90%)	4 (3.45%)	100 (86.21%)	4 (3.45%)	

2nd week	399	36 (9.02%)	11 (2.76%)	341 (85.46%)	11 (2.76%)	
3rd week	483	48 (9.94%)	10 (2.07%)	413 (85.51%)	12 (2.49%)	0.903
<b>Hospital Type</b>						
Teaching hospital	769 (77.05%)	71 (9.23%)	22 (2.86%)	658 (85.57%)	18 (2.34%)	
High volume non-teaching	212 (21.24%)	20 (9.43%)	2 (0.94%)	184 (86.79%)	6 (2.83%)	
Low volume non-teaching	17 (1.70%)	1 (5.88%)	1 (5.88%)	12 (70.59%)	3 (17.65%)	0.005

Variables are presented in numbers (%). The Chi-square test was used to compare groups. Minor clinical criteria: Fever, cough, and myalgia; Major clinical criteria: Low SpO<sub>2</sub>, shortness of breath, unconsciousness; Immunodeficiency includes HIV infection and AIDS, cancer, immunodeficiency disorders and receiving chemotherapy; Low volume hospitals indicate hospitals with less than 20 COVID-19 admitted patients.

Table 3: Comparing the study patients based on their PCR-test status

Variable	RT-PCR test status			RT-PCR test results		
	Tested N= 586	Not tested N= 412	P value	Test positive N= 440	Test negative N= 146	P value
<b>Sex</b>						
Female	243 (56.64%)	186 (43.36%)		188 (77.37%)	55 (22.63%)	
Male	343 (60.28%)	226 (39.72%)	0.248	252 (73.47%)	91 (26.53%)	0.283
<b>Age group</b>						
< 50 years	221 (54.98%)	181 (45.02%)		168 (76.02%)	53 (23.98%)	
51-60 years	101 (52.60%)	91 (47.40%)		73 (72.28%)	28 (27.72%)	
61-70 years	119 (63.64%)	68 (36.36%)		90 (75.63%)	29 (24.37%)	
≥ 70 years	145 (66.82%)	72 (33.18%)	0.005	109 (75.17%)	36 (24.83%)	0.908
<b>ICU Admission</b>						
Yes	39 (75.00%)	13 (25.00%)		22 (56.41%)	17 (43.59%)	
No	547 (57.82%)	399 (42.18%)	0.014	418 (76.42%)	129 (23.58%)	<b>0.005</b>
<b>Co-existing disorders</b>						
No	405 (55.25%)	328 (44.75%)		310 (76.54%)	95 (23.46%)	
Yes	181 (68.30%)	84 (31.70%)	<0.001	130 (71.82%)	51 (28.18%)	0.222
<b>≥ Comorbidities</b>	60 (75.00%)	20 (25.00%)	0.001	40 (66.67%)	20 (33.33%)	0.096

Cardiovascular Diseases	80 (72.73%)	30 (27.27%)	0.002	56 (70.00%)	24 (30.00%)	0.258
Chronic Pulmonary Diseases	22 (73.33%)	8 (26.67%)	0.099	16 (72.73%)	6 (27.27%)	0.794
Diabetes	74 (70.48%)	31 (29.52%)	0.010	54 (72.97%)	20 (27.03%)	0.653
Hypertension	38 (66.67%)	19 (33.33%)	0.209	26 (68.42%)	12 (31.58%)	0.326
Immunodeficiency	9 (56.25%)	7 (43.75%)	0.840	5 (55.56%)	4 (44.44%)	0.172
Chronic Renal Diseases	7 (70.00%)	3 (30.00%)	0.466	5 (71.43%)	2 (28.57%)	0.822
<b>Sign and symptoms</b>						
Any sign	551 (57.22%)	412 (42.78%)	<0.001	405 (73.50%)	146 (26.50%)	<b>&lt;0.001</b>
Fever	293 (53.76%)	252 (46.24%)	<0.001	224 (76.45%)	69 (23.55%)	0.445
Cough	376 (55.90%)	295 (44.10%)	0.010	288 (77.01%)	86 (22.99%)	0.153
Myalgia	159 (52.82%)	142 (47.18%)	0.013	119 (74.84%)	40 (25.16%)	0.934
Shortness of breath	301 (52.53%)	272 (47.47%)	<0.001	217 (72.09%)	84 (27.91%)	0.085
SpO <sub>2</sub> <93%	313 (51.14%)	299 (48.86%)	<0.001	221 (70.61%)	92 (29.39%)	<b>0.007</b>
Unconsciousness	22 (68.75%)	10 (31.25%)	0.241	11 (50.00%)	11 (50.00%)	<b>0.006</b>
<b>Outcome</b>						
Recovery	484 (54.94%)	397 (45.06%)		349 (72.11%)	135 (27.89%)	
Death	102 (87.18%)	15 (12.82%)	<0.001	91 (89.22%)	11 (10.78%)	<b>&lt;0.001</b>

<b>Admission week</b>						
1st week	53 (45·69%)	63 (54·31%)		33 (62·26%)	20 (37·74%)	
2nd week	249 (62·41%)	150 (37·59%)		200 (80·32%)	49 (19·68%)	
3rd week	284 (50·80%)	199 (41·20%)	0·006	207 (72·89%)	77 (27·11%)	<b>0·011</b>

Variables are presented in numbers (%). The Chi-square test was used to compare groups. Immunodeficiency includes HIV infection and AIDS, cancer, immunodeficiency disorders and receiving chemotherapy

Table 4: Associated factors of death in COVID-19 patients who were admitted to hospitals in Qazvin province

Subgroup	Number of death (%)	Odds ratio (95% CI)	P value
<b>Sex</b>			
Female	48 (11·19%)	Reference	
Male	69 (12·13%)	1·16 (0·74, 1·81)	0·511
<b>Age group</b>			
< 50 years	24 (5·97%)	Reference	
50-59 years	12 (6·25%)	0·97 (0·44, 2·11)	0·942
60-69 years	22 (11·76%)	1·73 (0·89, 3·35)	0·101
≥70 years	59 (27·19%)	5·15 (2·91, 9·12)	<b>&lt;0·001</b>
<b>ICU admission</b>			
No	92 (9·73%)	Reference	
Yes	25 (48·08%)	11·46 (5·53, 23·86)	<b>&lt;0·001</b>
<b>RT-PCR test status</b>			
Negative	11 (7·53%)	Reference	
Positive	91 (20·68%)	5·75 (2·65, 12·48)	<b>&lt;0·001</b>
Not tested	15 (3·64%)	0·74 (0·30, 1·84)	0·531
<b>Co-existing disorder</b>			
Without co-existing disorder	67 (9·14%)	Reference	
All	50 (18·87%)	1·4 (0·91, 2·34)	0·110
Two or more co-disorders	20 (25·02%)	1·82 (0·92, 3·60)	0·081
Cardiovascular diseases	26 (23·64%)	1·57 (0·86, 2·87)	0·186
Chronic pulmonary diseases	5 (16·67%)	1·28 (0·43, 3·79)	0·438
Diabetes	19 (18·10%)	1·39 (0·73, 2·64)	0·287
Chronic renal disease	4 (40·00%)	3·07 (0·55, 17·08)	0·164
Immunodeficiency	<b>5 (31·25%)</b>	<b>4·3 (1·11, 17·23)</b>	<b>0·035</b>
Hypertension	12 (21·05%)	0·99 (0·44, 2·20)	0·991
<b>Admission week</b>			



1 <sup>st</sup> Week	12 (10·34%)	Reference	
2 <sup>nd</sup> Week	47 (11·78%)	0·77 (0·32, 1·75)	0·536
3 <sup>rd</sup> Week	58 (12·01%)	0·92 (0·41, 2·05)	0·845
<b>Type of Hospital</b>			
Teaching Hospitals	93 (12·09%)	Reference	
High-Volume non-teaching	22 (10·38%)	0·61 (0·32, 1·11)	0·140
Low-Volume non-teaching	2 (11·76%)	0·23 (0·03, 1·55)	0·113

Multivariate logistic regression analysis was run to calculate odd ratios (95%CI). Immunodeficiency includes HIV infection and AIDS, cancer, immunodeficiency disorders, and receiving chemotherapy; Low volume hospitals indicate hospitals with less than 20 COVID-19 admitted patients.

Figure 1 – The study patients’ flow diagram

